Align Technology, Inc. (NASDAQ:ALGN) Director Susan E. Siegel Sells 1,400 Shares of Stock

Align Technology, Inc. (NASDAQ:ALGN) Director Susan E. Siegel sold 1,400 shares of the firm’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $273.93, for a total value of $383,502.00. Following the transaction, the director now owns 4,071 shares in the company, valued at $1,115,169.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

ALGN stock opened at $272.97 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.57 and a current ratio of 1.68. The stock has a market capitalization of $21.59 billion, a price-to-earnings ratio of 49.36, a PEG ratio of 1.91 and a beta of 2.06. Align Technology, Inc. has a 1 year low of $169.84 and a 1 year high of $334.64. The stock’s fifty day moving average is $274.34 and its two-hundred day moving average is $233.43.

Align Technology (NASDAQ:ALGN) last posted its earnings results on Wednesday, January 29th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.13. The company had revenue of $649.80 million for the quarter, compared to analysts’ expectations of $646.75 million. Align Technology had a return on equity of 30.06% and a net margin of 18.40%. The firm’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same period last year, the business posted $1.20 earnings per share. As a group, analysts predict that Align Technology, Inc. will post 5.99 EPS for the current fiscal year.

ALGN has been the topic of a number of recent research reports. Bank of America raised their target price on Align Technology from $220.00 to $240.00 and gave the company a “neutral” rating in a research note on Thursday, October 24th. Stifel Nicolaus raised their target price on Align Technology from $290.00 to $305.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Wolfe Research upgraded Align Technology from a “peer perform” rating to an “outperform” rating and set a $360.00 target price on the stock in a research note on Thursday, January 9th. Zacks Investment Research upgraded Align Technology from a “sell” rating to a “hold” rating and set a $262.00 target price on the stock in a research note on Friday, October 25th. Finally, Piper Sandler raised their target price on Align Technology from to in a research note on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $269.42.

Hedge funds and other institutional investors have recently modified their holdings of the stock. YHB Investment Advisors Inc. increased its stake in Align Technology by 16.5% in the 3rd quarter. YHB Investment Advisors Inc. now owns 3,822 shares of the medical equipment provider’s stock worth $691,000 after purchasing an additional 541 shares in the last quarter. SeaCrest Wealth Management LLC increased its stake in Align Technology by 87.4% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 2,858 shares of the medical equipment provider’s stock worth $517,000 after purchasing an additional 1,333 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Align Technology by 14.3% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,659 shares of the medical equipment provider’s stock worth $842,000 after purchasing an additional 583 shares in the last quarter. Strategic Blueprint LLC purchased a new position in Align Technology in the 3rd quarter worth about $102,000. Finally, Summit Creek Advisors LLC purchased a new position in Align Technology in the 3rd quarter worth about $337,000. Institutional investors and hedge funds own 82.00% of the company’s stock.

Align Technology Company Profile

Align Technology, Inc, a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, and restorative and aesthetic dentistry worldwide. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as compliance indicators and compensation for tooth eruption; Invisalign Assist treatment, which offers support to dental practitioners throughout the treatment process, including progress tracking; and Invisalign First Phase I and Invisalign First Comprehensive Phase II package for younger patients with early mixed dentition with a mixture of primary/baby and permanent teeth.

Recommended Story: What is a death cross?

Insider Buying and Selling by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.